In Stockholm, Sweden, the The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) recently gathered experts and companies working on multiple sclerosis. Among the presenters were the Danish antibody developer Genmab, which presented results from its drug ofatumumab, which is licensed to Novartis.
In two phase III trials, the ability of the antibody drug to prevent relapse proved vastly superior to that of teriflunomide, an oral drug routinely used to treat relapsing forms of multiple sclerosis. A very promising result indeed for the patients, and MVA would like to congratulate our member company, Genmab, with yet another groundbreaking result!
Read full Labiotech-article here
The post MVA-member company, Genmab, presents new data on next-generation treatments for multiple sclerosis appeared first on MVA.